Personal profile
Biography
Harry Heijerman earned his MD (1984, cum laude) and his PhD in 1991 ("Studies in the clinical management of Cystic Fibrosis") He registered as pulmonologist in 1989, all above at the Leiden University Medical School. From 1996 till 2017 he was head of the department of Pulmonology at the Haga teaching Hospital in The Hague. Since 2017 he is head of the Department of Pulmonology and professor at the University Medical Center Utrecht The Netherlands. During his whole career he focussed on optimization of treatment for people with Cystic Fibrosis. He was PI of multiple mono and multi center studies focusing on understanding and treating Cystic Fibrosis. In 2002 he was the founding editor of the "Journal of Cystic Fibrosis". At present he is involved in several clinical studies addressing CFTR function in Cystic Fibrosis with the aim to find a cure for this life long inheritable disease, This work is done in close collaboration with the department of Pediatric Pulmonology.
External positions
Voorzitter adviesraad zorg - Expertise op het gebied van Cystic Fibrosis in mijn functie van longarts - Nederlandse Cystic Fibrosis stichting
1 Apr 2017 → 31 Dec 3999
Collaborations and top research areas from the last five years
-
Functional, Cohort-Level Assessment of CFTR Modulator Responses Using Biobanked Nasal Epithelial Cells from Individuals with Cystic Fibrosis
Aalbers, B. L., Amatngalim, G. D., Aarts, E. M., Rodenburg, L. W., den Hertog-Oosterhoff, L. A., Heijerman, H. G. M. & Beekman, J. M., Jan 2026, In: Journal of Personalized Medicine. 16, 1, 51.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile2 Downloads (Pure) -
Side versus adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in people with CF
Gorgels, J. B. A., Koopman, J., van der Hout, E. C., Hofland, R. W., Heijerman, H. G. M. & Bronsveld, I., Mar 2026, In: Respiratory Medicine. 253, 108697.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Evaluation of Elexacafor/Tezacaftor/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study
van Gemert, J. P., Luijk, B., Hellemons, M. E., Visser, K. A., Hansen, C. M. E., van der Meer, R., Gan, C. T., van der Vaart, H., Akkerman, O. W., Steenhuis, W. N., Verkleij, M., Heijerman, H. G. M., Verschuuren, E. A. M. & KOALA study group, Feb 2025, In: JHLT Open. 7, 9 p., 100210.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile2 Downloads (Pure) -
Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports
van Mourik, P., van der Hout, E. C., Luijk, H. D., Hofland, R. W., Bruns, A. H. W., Heijerman, H. G. M. & Bronsveld, I., Jan 2025, In: Respiratory Medicine Case Reports. 57, 102278.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile10 Downloads (Pure) -
Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy
Burgel, P.-R., Ballmann, M., Drevinek, P., Heijerman, H., Jung, A., Mainz, J. G., Peckham, D., Plant, B. J., Schwarz, C., Taccetti, G. & Smyth, A., 3 May 2024, In: BMJ open respiratory research. 11, 1, p. 1-9 9 p., e002049.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile7 Downloads (Pure)